LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

Home・Aktien・Vivani Medical

Vivani Medical

Open

1.39 2.21

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.34

Max

1.42

Schlüsselkennzahlen
By Trading Economics
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+198.51% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-15M 89M
Vorheriger Eröffnungskurs	-0.82
Vorheriger Schlusskurs	1.39

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Dez. 2025, 23:21 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. Dez. 2025, 23:14 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. Dez. 2025, 22:01 UTC

Wichtige Markttreiber

Costco Wholesale Reports Higher Monthly Sales

3. Dez. 2025, 21:38 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. Dez. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. Dez. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. Dez. 2025, 23:10 UTC

Ergebnisse

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. Dez. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. Dez. 2025, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5M

3. Dez. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. Dez. 2025, 22:20 UTC

Ergebnisse

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. Dez. 2025, 22:19 UTC

Ergebnisse

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. Dez. 2025, 22:17 UTC

Ergebnisse

Salesforce Working to Add Voice to Agentforce, CEO Says

3. Dez. 2025, 22:16 UTC

Ergebnisse

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. Dez. 2025, 22:15 UTC

Ergebnisse

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. Dez. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. Dez. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Dez. 2025, 21:49 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:23 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. Dez. 2025, 21:19 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:06 UTC

Ergebnisse

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. Dez. 2025, 21:03 UTC

Ergebnisse

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

198.51% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 198.51%

Hoch 4 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.